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Low-fat high-carbohydrate diet and plasma sex
hormones
Sir
The paper of Boyd et al ( 1997) (BrJ Cancer 76: 127-135) reports
the results of randomization of 220 premenopausal women to a
low-fat intake (21.2%c energy from fat) or to a control diet (33.1%7
energy from fat) for 2 years: this is both the largest and the longest
duration controlled trial that has been published and the results are
therefore ofgreat interest. At the end ofthe trial. serum concentra-
tions ofoestradiol and progesterone were significantly lower in the
intervention group than in the control group (by 20%c and 35%7
respectively), although the differences between groups in the
changes in these hormones during the trial were small and were
not statistically significant. The authors pointed out that the differ-
ences between groups at the end of the trial appeared to be due to
long menstrual cycles in a small number of subjects in the inter-
vention group and sugrested that the low-fat diet may have accel-
erated the onset of menopausal changes. This would be a very
important findina. but some further details would be helpful in
interpreting the results.
One possibility that should be checked is whether. by chance. a
higher proportion of the intervention group than of the control
group was entering menopause at the berinning ofthe trial. This is
a possibility because there were 50.9%c of women in the interven-
tion group but only 43.3% ofwomen in the control group aged 45+
years at baseline and because median baseline FSH was 18%c
higher in the intervention group (P = 0.08). Did any subjects have
baseline FSH concentrations suggestive ofthe onset ofmenopause
(>30 IU 1-')? Some information on the date of the last menstrual
period was collected at baseline, this could not be used to interpret
the values of the baseline hormone assays. but it might provide
some information on whether any of the subjects had very long
menstrual cycles at baseline and whether this differed between
groups. Could the authors provide a table of days since last
menstrual period at baseline by dietarv group.
Figure 1 in the paper shows that. at the end of the trial. there
were eight women in the intervention group but only two woomen
in the control group who reported that it was more than 50 days
since their last menstrual period. It would be useful to know the
aaes of these ten women and their FSH values at baseline and at 2
years (these can only be roughly estimated from the Figure). It
might also be interesting to divide the data by age to see whether
the effect is concentrated at ages 45 years and above and whether
there is any difference between groups below age 45 years.
The authors state that the difference in dietary fibre intake
between the intervention and control groups at 2 years was statisti-
cally significant. which could imply that the hormonal differences
were influenced by the change in fibre intake. However. the differ-
ence in fibre intakes was small. and the data in Table 2 indicate
that it was not statistically significant.
TJ Kev
Imperial Cancer Research Fund, CancerEpidemiology Unit,
Gibson Building, Radcliffe Infirmary; Oxford OX2 6HE, UK
Low-fat high-carbohydrate diet and plasma sex
hormones - reply
Sir
We thank your correspondent for their letter and reply to the ques-
tions in the order in which they were posed.
1. The number of subjects with baseline FSH levels greater than
30 IU L-1 was nine for the intervention group (1) and 11 for the
controls (C). The mean values ofFSH for those with values
over 30. were 52.8IU L-1 (I) and 57.4ILTL-1 (C).
2. The number ofdays from the last menstrual period at baseline
is not available. We did. however. collect infonnation about
maximum cycle length. For the intervention group (I) and for
controls (C) the maximum cycle length was as follows:
C
Mean 29.3 28.5
Median 28.0 28.0
Interquarble range 28-30 27.5-30
3. For the ten women who reported more than 50 days since last
period at 2 years. their ages and FSH values [mean (median)]
were:
Group n Age (years) FSH baseline FSH 2 year
8 47.4 (49) 25.6 (22) 134.9 (150.5)
C 2 45 (45) 41 (41) 47 (47)
4. Division ofthe data at age 45 years showed similar findings to
those shown in Table 3 of our paper. In women under age 45
vears. the median oestradiol level in the intervention group (n
= 55) was 306 [interquartile range (IQR) 183-514] at baseline
and 275 (IQR 134-450) at 2 years. In controls (n = 59) the
values were 274 (IQR 165-438) at baseline and 352 (IQR
172-450) at 2 years. The difference in median levels at 2 vears
was not statistically significant (P = 0.41). In women aged
over 45 years at entry. the median oestradiol level in the inter-
vention group (n = 57) was 259 (IQR 191-445) at baseline and
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270 (IQR 96-457) at 2 years. In controls (n = 45) the values
were 367 (230-475) at baseline and 345 (IQR 245-455) at 2
vears. The difference in median levels at 2 years was statisti-
callv sianificant (P = 0.03).
5. The difference in fibre intake shown in Table 2 is not statisti-
cally significant. However. in the trial as a whole. when the
difference in fibre intake is the same but the number of
subjects is ofcourse much larger. the difference between inter-
vention and control groups is highly sianificant.
We thus find no evidence to support the suggestion that a higher
proportion of the intervention group was entering menopause at
baseline. However. it does seem that the main effect ofthe dietary
intervention on oestradiol levels may be in women over 45 years.
although this conclusion is based on small numbers and is obvi-
ouslv preliminary.
NBovd
Div-ision ofEpidemiology and Statistics. Ontario Cancer Institute,
Princess Margaret Hospital. Toronto. Ontario. Canada
Basal cell carcinoma of the face: surgery or
radiotherapy? Results of a randomized study
Sir,
I read with interest the recent paper by Avril et al ( 1997
describing the results of a prospective study comparing surgery
and radiotherapy in the management of basal cell carcinomas
(BCCs) of the face in 347 patients. Because both tumour recur-
rence rates and cosmesis were found to be significantly better in
the surgically managed group. the authors concluded that surgery
should be considered as the first-line treatment ofchoice for facial
BCCs less than 4 cm in diameter.
While there is undoubtedly a need for good randomized
prospective trials comparing the effectiveness ofthe two treatment
options. this study did not address the issues of management as
they are commonly encountered in current clinical practice. In the
study. the authors compared the treatment modalities in patients
with a wide range of clinical presentations. The size of tumours.
for example. ranged from 3-5 mm (10%c) to 31-40 mm (0.9%c) in
diameter. with 57%7c of tumours < 10 mm and 93%c <20 mm. Most
lesions were non-ulcerated nodules clinically. with a smaller
number of superficial (22%c) and morphoeic-type BCCs (4%7c). The
affected sites included the forehead. cheeks. chin. ears and nose.
It is perhaps these broad inclusion criteria that weakened the
overall value ofthe trial. One ofthe fundamental principles ofskin
cancer management is. wxhen possible. to completely remove
tumours (Flemingy et al. 1995). In practice. most dermatologists
would opt for excision of lesions if it were both technically
possible and likely to give good cosmetic results. As the majority
of BCCs in both treatment groups were < 1 cm in diameter. it
seems likelT that many of these tumours would have been
amenable to simple surgical excision with primary closure. In
those cases treated with radiotherapy. surgical intervention would
not only have avoided multiple outpatient visits. or even lengthy
inpatient stays. but would have permitted histological assessment
ofresection margins.
In their conclusions. the authors stated that. for facial BCCs less
than 4 cm in diameter. surgery is the treatment ofchoice. It is well
recognized that radiotherapy has a valuable role in the manage-
ment of particular clinical problems. such as tumours affectinc,
cartilaginous areas and the treatment of large ulcerated lesions
often encountered in elderly patients (Fleming et al. 1995). This
conclusion. while undoubtedly true for small lesions amenable to
excision. disregards the usefulness of radiotherapy in the manage-
ment oflarger and more awkwardly situated lesions.
Dr Susan Holmes
Department ofDermatologY,
University ofGlasgowz
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Expression of bcJl2 protein in follicular lymphomas:
a report from a south Indian hospital
Sir,
The t 14:18) translocation juxtaposes part of the immunoglobulin
heavy-chain gene on chromosome 14 with the bcl-2 gene on chro-
mosome 18. This translocation was discovered in most follicular-
centre cell lymphoma. The prevalance of t( 1418) shows a
geographical predilection. being highest in the USA and lowest in
Japan (Isaacson. 1991 ). The bcl-2 oncoprotein can be easily local-
ized using immunohistochemical staining. and this has been
studied in follicular lymphomas occumrng in the West. We
assessed the frequency of bcl-2 expression in follicular
lymphomas in 51 subjects from the Indian subcontinent.
Out of a total of 406 cases of non-Hodgkin's lymphoma diag-
nosed from 1 March 1995 to 30 September 1997. 55 were follic-
ular l-mphoma (1 3.5%). Formalin-fixed paraffin-embedded tissue
samples for immunohistochemistrv w-ere available in only 51 of
these cases. Immunohistochemical analysis was performed on
C) Cancer Research Campaign 1998 British Joumal ofCancer (1998) 78(9). 1256-1258